The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort

Oncotarget

Volumn 8, Issue 16, 2017, Pages 26789-26801

  Ness, Nora ^a   Andersen, Sigve ^a,b   Khanehkenari, Mehrdad Rakaee ^a   Nordbakken, Cecilie V ^b   Valkov, Andrej ^b   Paulsen, Erna Elise ^a,b   Nordby, Yngve ^a,b   Bremnes, Roy M ^a,b   Donnem, Tom ^a,b   Busund, Lill Tove ^a,b   Richardsen, Elin ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Immunohistochemistry; PD 1; PDL 1; Prognostic marker; Prostate cancer

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; COHORT ANALYSIS; DISEASE ASSOCIATION; EPITHELIUM CELL; FAILURE FREE SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; CANCER ASSOCIATED FIBROBLAST; CANCER GRADING; CLINICAL TRIAL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REPRODUCIBILITY; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CANCER-ASSOCIATED FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 85017503544     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15817     Document Type: Article

References (49)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer Incidence and Mortality Worldwide. GLOBOCAN 2012 v1.0. 2013; IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer
2. Hu Y, Zhao Q, Rao J, Deng H, Yuan H, Xu B. Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000-2009. BMC Public Health. 2014; 14:356. doi: 10.1186/1471-2458-14-356
3. Van der Kwast TH, Roobol MJ. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol. 2013; 10:473-82. doi: 10.1038/nrurol.2013.112
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-60
5. Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2016; 20:256-61. doi: 10.1097/PPO.0000000000000061
6. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2015; 27:409-16. doi: 10.1093/annonc/mdv615
7. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331
8. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192:1027-34. doi: 10.1084/jem.192.7.1027
9. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015; 23:32-8
10. Gridelli C, Besse B, Brahmer JR, Crinò L, Felip E, de Marinis F. The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2016. doi: 10.1016/j.cllc.2016.01.004
11. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28:3167-75. doi: 10.1200/JCO.2009.26.7609
12. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-54. doi: 10.1056/NEJMoa1200690
13. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin Cancer Res. 2014; 20:5064-74. doi: 10.1158/1078-0432.CCR-13-3271
14. Andersen S, Richardsen E, Nordby Y, Ness N, Størkersen O, Al-Shibli K, Donnem T, Bertilsson H, Busund LT, Angelsen A, Bremnes RM. Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSAdoubling time. BMC Urol. 2014; 14:49. doi: 10.1186/1471-2490-14-49
15. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015; 162:1242-56. doi: 10.1016/j.cell.2015.08.052
16. Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, Busund LT, Bremnes RM, Richardsen E. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate. 2014; 74:1452-61. doi: 10.1002/pros.22862
17. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, et al. PD-1 identifies the patientspecific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014; 124:2246-59. doi: 10.1172/JCI73639
18. Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, et al. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Target Oncol. 2015
19. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate. 2009; 69:1694-703. doi: 10.1002/pros.21020
20. Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer. 2009; 45: 1664-72. doi: 10.1016/j.ejca.2009.02.015
21. Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM, Drake CG. A Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015; 18:325-32. doi: 10.1038/pcan.2015.39
22. Gevensleben H, Dietrich D1, Golletz C, Steiner S, Jung M, Thiesler T, Majores M, Stein J, Uhl B, Müller S, Ellinger J, Stephan C, Jung K, et al. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clin Cancer Res. 2016; 23: 1969-77. doi: 10.1158/1078-0432.CCR-15-2042
23. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013; 5:1-27. doi: 10.1126/scitranslmed.3006504
24. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015; 51:221-8. doi: 10.1016/j.oraloncology.2014.11.014
25. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M. Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discov. 2013; 3:1355-63. doi: 10.1158/2159-8290.CD-13-0310
26. Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR,Freeman GJ, Ferris RL. Identification of the Cell-Intrinsic and-Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2016; 76:1031-43. doi: 10.1158/0008-5472.CAN-15-2001
27. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007; 13:84-8. doi: 10.1038/nm1517
28. Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y, Zhou H, Li R, Wang K, Wang W, Hua D, Zhang X. MiR-20b,-21, and-130b inhibit PTEN expression resulting in B7-H1 overexpression in advanced colorectal cancer. Hum Immunol. 2014; 75: 348-53. doi: 10.1016/j.humimm.2014.01.006
29. Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer. 2013; 49: 1273-9. doi: 10.1016/j.ejca.2012.11.035
30. Chen X, Du Y, Lin X, Qian Y, Zhou T, Huang Z. CD4+CD25+ regulatory T cells in tumor immunity. Int Immunopharmacol. 2016; 34:244-9. doi: 10.1016/j. intimp.2016.03.009
31. Davidsson S, Ohlson AL, Andersson SO, Fall K, Meisner A, Fiorentino M, Andrén O, Rider JR. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol. 2013; 26: 448-55. doi: 10.1038/modpathol.2012.164
32. Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012; 33:364-72. doi: 10.1016/j. it.2012.02.006
33. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114:1537-44. doi: 10.1182/blood-2008-12-195792
34. Japp AS, Kursunel MA, Meier S, Mälzer JN, Li X, Rahman NA, Jekabsons W, Krause H, Magheli A, Klopf C, Thiel A, Frentsch M. Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression. Cancer Immunol Immunother. 2015; 64: 1487-94. doi: 10.1007/s00262-015-1752-y
35. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015; 6:e1792. doi: 10.1038/cddis.2015.162
36. Godin-Ethier J, Hanafi L-A, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res. 2011; 17:6985-91. doi: 10.1158/1078-0432.CCR-11-1331
37. Fernández-García EM, Vera-Badillo FE, Perez-Valderrama B, Matos-Pita AS, Duran I. Immunotherapy in prostate cancer: review of the current evidence. Clin Transl Oncol. 2015; 17:339-57. doi: 10.1007/s12094-014-1259-6
38. Koh YT, Gray A, Higgins SA, Hubby B, Kast WM. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate. 2009; 69:571-84. doi: 10.1002/pros.20906
39. Sobol I, Thompson RH, Dong H, Krco C, Kwon ED. Immunotherapy in prostate cancer. Curr Urol Rep. 2015; 16: 34. doi: 10.1007/s11934-015-0509-7
40. Drake CG, Doody ADH, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, McGary PW, Coryell L, Nelson WG, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005; 7: 239-49
41. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001; 98:14565-70
42. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, Blazar BR, Millar JL, Malin MA, Chidgey AP, Boyd RL. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol. 2005; 175:2741-53. doi: 10.4049/jimmunol.175.4.2741
43. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015; 14:847-56. doi:10.1158/1535-7163.MCT-14-0983
44. Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016; 7:52810-52817. doi: 10.18632/oncotarget.10547
45. Eble J, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Eble J, Sauter G, Epstein JI, Sesterhenn IA, editors. Lyon: IARC Press; 2004
46. Helpap B, Egevad L. Modified Gleason grading. An updated review. Histol Histopathol. 2009; 24:661-6
47. Epstein JI. An update of the Gleason grading system. J Urol. 2010; 183:433-40. doi: 10.1016/j.juro.2009.10.046
48. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2015; 69:428-35. doi: 10.1016/j.eururo.2015.06.046
49. UICC. TNM Classification of Malignant Tumours. 7th ed. Sobin LH, Gospodarowicz MK, Wittekind C, editors. Wiley-Blackwell; 2009. 336